中性粒细胞/淋巴细胞比值在冠心病诊疗中的研究进展

doi:10.3969/j.issn.1673-8640.2026.03.014

检验医学 ›› 2026, Vol. 41 ›› Issue (3): 291-298.DOI: 10.3969/j.issn.1673-8640.2026.03.014

中性粒细胞/淋巴细胞比值在冠心病诊疗中的研究进展

徐洪强¹, 彭海波¹, 徐欢², 罗中兰³, 熊光海¹, 李振¹, 罗杰¹()

^1. 中国人民解放军陆军第954医院检验病理科，西藏山南 856000
^2. 中国人民解放军西藏军区总医院检验科，西藏拉萨 850000
^3. 重庆市精神卫生中心检验科，重庆江北 401147

收稿日期:2024-11-25 修回日期:2025-04-24 出版日期:2026-03-30 发布日期:2026-04-14
通讯作者: 罗杰
作者简介:罗杰，E-mail：luojie3600@126.com。
徐洪强，男，1993年生，学士，主治医师，主要从事临床医学检验工作。
基金资助:
中国人民解放军陆军第954医院高原医学中心建设项目(QJGYYXYJZX-018)

Research progress on neutrophil-to-lymphocyte ratio in the diagnosis and treatment of coronary heart disease

XU Hongqiang¹, PENG Haibo¹, XU Huan², LUO Zhonglan³, XIONG Guanghai¹, LI Zhen¹, LUO Jie¹()

^1. Department of Clinical Laboratory and Pathology， the 954th Hospital of Chinese People's Liberation Army， Shannan 856000，Xizang， China
^2. Department of Clinical Laboratory， General Hospital of Xizang Military Command， Lhasa 850000，Xizang， China
^3. Department of Clinical Laboratory， Chongqing Mental Health Center， Chongqing 401147， China

Received:2024-11-25 Revised:2025-04-24 Online:2026-03-30 Published:2026-04-14
Contact: LUO Jie

摘要/Abstract

摘要：

冠心病（CHD）是常见的心血管疾病，其患病率和死亡率均逐年上升，且发病年龄趋于年轻化，严重威胁人类生命安全。为缓解CHD给社会带来的巨大压力，寻找医疗成本低，且快速、简单的诊断工具意义重大。炎症标志物中性粒细胞/淋巴细胞比值（NLR）作为新的无创评估CHD患者心肌缺血程度的生物标志物，在CHD的诊断、病情严重程度评估、预后判断等方面具有重要应用价值。文章对CHD的流行病学特征、炎症与CHD的关系，以及炎症标志物NLR在CHD中的研究进展进行综述，为临床充分认识NLR在CHD诊疗方面的潜在价值提供参考。

关键词: 中性粒细胞/淋巴细胞比值, 冠心病, 炎症反应

Abstract:

Coronary heart disease（CHD）as a common cardiovascular disease，had an increasing incidence and mortality rate year by year，and the age of onset tends to be younger，posing a serious threat to human life safety. It is of significance to find inexpensive，fast and simple diagnostic tools to alleviate the enormous pressure that CHD brings to society. Inflammatory biomarker neutrophil-to-lymphocyte ratio（NLR）had been a novel non-invasive biomarker for assessing the degree of myocardial ischemia in CHD patients，it plays a role in the diagnosis，severity assessment and prognosis judgement of CHD. This review focuses on the epidemiology of CHD，the relationship between inflammation and CHD and the current research status of inflammatory biomarker NLR in the field of CHD，providing a reference for further understanding the potential of NLR in the diagnosis and treatment of CHD.

Key words: Neutrophil-to-lymphocyte ratio, Coronary heart disease, Inflammatory response

中图分类号:

R446.1

徐洪强, 彭海波, 徐欢, 罗中兰, 熊光海, 李振, 罗杰. 中性粒细胞/淋巴细胞比值在冠心病诊疗中的研究进展[J]. 检验医学, 2026, 41(3): 291-298.

XU Hongqiang, PENG Haibo, XU Huan, LUO Zhonglan, XIONG Guanghai, LI Zhen, LUO Jie. Research progress on neutrophil-to-lymphocyte ratio in the diagnosis and treatment of coronary heart disease[J]. Laboratory Medicine, 2026, 41(3): 291-298.

图/表 1

参考文献 49

[1]	AGRAWAL H, CHOY H K, LIU J, et al. Coronary artery disease[J]. Arterioscler Thromb Vasc Biol, 2020, 40(7):e185-e192.
[2]	ALIE N, ELDIB M, FAYAD Z A, et al. Inflammation,atherosclerosis,and coronary artery disease:PET/CT for the evaluation of atherosclerosis and inflammation[J]. Clin Med Insights Cardiol, 2015, 8(Suppl 3):13-21.
[3]	中国心血管健康与疾病报告编写组. 《中国心血管健康与疾病报告2022》概要[J]. 中国介入心脏病学杂志, 2023, 31(7):485-508.
[4]	SAFIRI S, KARAMZAD N, SINGH K, et al. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories,1990-2019[J]. Eur J Prev Cardiol, 2022, 29(2):420-431. DOI URL
[5]	BUDZIANOWSKI J, PIESZKO K, BURCHARDT P, et al. The role of hematological indices in patients with acute coronary syndrome[J]. Dis Markers, 2017, 2017:3041565.
[6]	沈正军. 冠心病合并高脂血症患者血脂水平与主要炎症因子的相关性[J]. 心血管康复医学杂志, 2017, 26(4):388-390.
[7]	臧贵明, 曹毅, 王杰. 糖尿病合并冠心病患者血清HMGB1、ET-1、MIF含量变化及其与炎症因子的相关性[J]. 心血管康复医学杂志, 2016, 25(2):129-132.
[8]	于高修, 陈峰. 补体C1q/肿瘤坏死因子相关蛋白在冠心病中的研究进展[J]. 中国临床医学, 2022, 29(1):105-110.
[9]	万虎, 刘莹, 黄拓, 等. NLRP3炎性小体及其在心血管疾病中的作用研究的进展[J]. 心血管康复医学杂志, 2023, 32(2):204-207.
[10]	VAKHSHOORI M, NEMATI S, SABOUHI S, et al. Neutrophil to lymphocyte ratio(NLR)prognostic effects on heart failure;a systematic review and meta-analysis[J]. BMC Cardiovasc Disord, 2023, 23(1):555. DOI
[11]	XIANG F, CHEN R, CAO X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients:a prospective cohort study[J]. Hemodial Int, 2018, 22(1):82-92. DOI URL
[12]	ZHAN Y, XU T, TAN X. Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome:atherogenic index of plasma,neutrophil-lymphocyte ratio[J]. BMC Cardiovasc Disord, 2016, 16:96. DOI URL
[13]	BHAT T M, AFARI M E, GARCIA L A. Neutrophil lymphocyte ratio in peripheral vascular disease:a review[J]. Expert Rev Cardiovasc Ther, 2016, 14(7):871-875. DOI URL
[14]	TURKMEN K, GUNEY I, YERLIKAYA F H, et al. The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients[J]. Ren Fail, 2012, 34(2):155-159. DOI PMID
[15]	BUONACERA A, STANCANELLI B, COLACI M. Neutrophil to lymphocyte ratio:an emerging marker of the relationships between the immune system and diseases[J]. Int J Mol Sci, 2022, 23(7):3636. DOI URL
[16]	陈梦婷, 余清萍, 李雨, 等. 血清PCT、NLR及CRP水平与急性胰腺炎严重程度的相关性[J]. 西部医学, 2021, 33(12):1849-1853.
[17]	VINCENT A, C A S. Predicting severity of acute pancreatitis-evaluation of neutrophil-to-lymphocyte count ratio as emerging biomarker:a retrospective analytical study[J]. Cureus, 2024, 16(11):e74881.
[18]	ERTURK S B, TUKENMEZ T E, ILGIN C, et al. Prognostic values of baseline cortisol levels and neutrophil to lymphocyte ratio in COVID-19[J]. J Med Biochem, 2023, 42(3):437-443. DOI PMID
[19]	张兵华, 王晓坤, 许朝晖, 等. 中性粒细胞/淋巴细胞比值对新型冠状病毒肺炎患者死亡风险的预测价值[J]. 临床肺科杂志, 2020, 25(12):1791-1794.
[20]	CHEN J, YASREBINIA S, GHAEDI A, et al. Meta-analysis of the role of neutrophil to lymphocyte ratio in neonatal sepsis[J]. BMC Infect Dis, 2023, 23(1):837. DOI PMID
[21]	陈素云, 赵志新, 颜海希, 等. 中性粒细胞与淋巴细胞比率和前白蛋白对脓毒血症患者预后评价研究[J]. 中国卫生检验杂志, 2019, 29(20):2524-2527.
[22]	STONER L, LUCERO A A, PALMER B R, et al. Inflammatory biomarkers for predicting cardiovascular disease[J]. Clin Biochem, 2013, 46(15):1353-1371. DOI PMID
[23]	高顶, 赵茜, 高磊, 等. sST2、NLR与冠心病预测诊断及严重程度相关性分析[J]. 分子诊断与治疗杂志, 2023, 15(10):1685-1688.
[24]	薛雅芝, 曾晓容, 林子祥, 等. C反应蛋白高密度脂蛋白胆固醇比值、中性粒细胞淋巴细胞比值对冠心病的预测价值研究[J]. 中国全科医学, 2020, 23(25):3194-3199. DOI
[25]	TANGJITGAMOL S, UDAYACHALERM W, WANISHSAWAD C, et al. Association of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and coronary artery disease among the physicians[J]. J Inflamm Res, 2024, 17:59-66. DOI PMID
[26]	李梦兰, 梁宾, 曹树正, 等. 系统性炎症指数在冠心病中的临床意义及诊断价值研究[J]. 国际检验医学杂志, 2021, 42(19):2329-2332.
[27]	WANG Y, ZHUANG Y, LIN C, et al. The neutrophil-to-lymphocyte ratio is associated with coronary heart disease risk in adults:a population-based study[J]. PLoS One, 2024, 19(2):e0296838. DOI URL
[28]	胡道军, 郁淼, 张洪磊, 等. 基于Logistic回归和ROC曲线综合评价IMA,NLR,hs-CRP和CK-MB联合检测对早期急性心肌梗死的诊断价值[J]. 现代检验医学杂志, 2016, 31(5):76-80.
[29]	林子娜, 李荣. FIBC、NLR测定联合中医辨证在冠心病预测中的应用[J]. 中国中医急症, 2022, 31(10):1730-1734.
[30]	张媛媛, 张永林, 孔悦, 等. 256层螺旋CT联合NLR及D-二聚体检测诊断冠脉斑块稳定性的临床价值[J]. 中国CT和MRI杂志, 2022, 20(1):92-94.
[31]	GU N, CHEN P, WANG X, et al. Association between the neutrophil-to-lymphocyte ratio and in-stent neoatherosclerosis and plaque vulnerability:an optical coherence tomography study[J]. J Cardiovasc Pharmacol, 2024, 84(5):506-514. DOI URL
[32]	于艳华, 谢文瑞. 冠心病患者NLR及BMP4、ANGPLT8水平检测的临床意义[J]. 检验医学与临床, 2022, 19(14):1961-1965.
[33]	AHMAD N, RAZA M T, ALI M A, et al. Correlation between the neutrophil-to-lymphocyte ratio and the severity of coronary artery disease in patients with myocardial infarction[J]. Cureus, 2024, 16(9):e69061.
[34]	刘金艳, 尹育华, 刘建伟, 等. 红细胞分布宽度和半乳糖凝集素3及中性粒细胞淋巴细胞比值与冠心病并发心房颤动关系及意义[J]. 中国心血管病研究, 2023, 21(1):40-44.
[35]	WADA H, DOHI T, MIYAUCHI K, et al. Neutrophil to lymphocyte ratio and long-term cardiovascular outcomes in Coronary artery disease patients with low high-sensitivity C-reactive protein level[J]. Int Heart J, 2020, 61(3):447-453. DOI PMID
[36]	SHIN H C, JANG J S, JIN H Y, et al. Combined use of neutrophil to lymphocyte ratio and C-reactive protein level to predict clinical outcomes in acute myocardial infarction patients undergoing percutaneous coronary intervention[J]. Korean Circ J, 2017, 47(3):383-391. DOI URL
[37]	CHEN Q, DAI X W, DONG Q Q, et al. Association of NLR with all-cause and cardiovascular mortality in adults with coronary heart disease:1999-2018 NHANES data analysis[J]. Medicine(Baltimore), 2024, 103(50):e40844.
[38]	王楠, 郑迪, 宋毓青, 等. 外周血中性粒细胞与淋巴细胞比值与急性心肌梗死病情及预后的关系[J]. 内科理论与实践, 2020, 15(6):369-374.
[39]	张朝义, 刘泽森, 孟康. 中性粒细胞与淋巴细胞比值对冠心病患者预测价值的Meta分析[J]. 心肺血管病杂志, 2019, 38(7):773-780.
[40]	王玎羽, 林菁榕, 崔玉敏, 等. 中性粒细胞-淋巴细胞比值在冠心病经皮冠状动脉介入治疗中的临床意义[J]. 局解手术学杂志, 2023, 32(7):607-611.
[41]	HUO L K, CHEN K Y, TSE G, et al. Association of inflammatory markers based on routine blood with prognosis in patients underwent percutaneous coronary intervention[J]. Medicine(Baltimore), 2024, 103(19):e38118.
[42]	SONG S, CHEN L, YU R, et al. Neutrophil-to-lymphocyte ratio as a predictor of all-cause and cardiovascular mortality in coronary heart disease and hypertensive patients:a retrospective cohort study[J]. Front Endocrinol(Lausanne), 2024, 15:1442165.
[43]	HE J, BIAN X, SONG C, et al. High neutrophil to lymphocyte ratio with type 2 diabetes mellitus predicts poor prognosis in patients undergoing percutaneous coronary intervention:a large-scale cohort study[J]. Cardiovasc Diabetol, 2022, 21(1):156. DOI
[44]	MERDLER I, CHITTURI K R, CHATURVEDI A, et al. Coronary microvascular dysfunction and inflammation:insights from the coronary microvascular disease registry[J]. Cardiovasc Revasc Med, 2024, 69:30-34. DOI URL
[45]	ZHANG D, ZHU Y, LI H, et al. Associations of whole blood zinc levels with coronary artery calcification and future cardiovascular events in CKD patients[J]. Biol Trace Elem Res, 2024, 202(1):46-55. DOI
[46]	WU H, LIAO B, JI T, et al. Comparison between traditional logistic regression and machine learning for predicting mortality in adult sepsis patients[J]. Front Med(Lausanne), 2025, 11:1496869.
[47]	NILSSON L, WIERINGA W G, PUNDZIUTE G, et al. Neutrophil/lymphocyte ratio is associated with non-calcified plaque burden in patients with coronary artery disease[J]. PLoS One, 2014, 9(9):e108183. DOI URL
[48]	ATTIQ A, AFZAL S, AHMAD W, et al. Hegemony of inflammation in atherosclerosis and coronary artery disease[J]. Eur J Pharmacol, 2024, 966:176338.
[49]	HENRIK KRISTENSEN J, AMALIE WISTISEN KOCZULAB C, ANTON FRANDSEN E, et al. Kinetics of cardiac troponin and other biomarkers in patients with ST elevation myocardial infarction[J]. Int J Cardiol Heart Vasc, 2023, 48:101250.

临床价值	作用	参考文献
诊断价值
升高	NLR≥2.36可作为CHD的独立危险因素	[27]
升高	NLR升高1个单位，CHD发病率增加1.6倍，诊断CHD的AUC为0.814	[26]
升高	结合CK-MB、hs-CRP、IMA诊断CHD的AUC为0.980	[28]
升高	结合中医辨证和Fib诊断CHD的AUC为0.776	[29]
病情严重程度评估价值
升高	预示着CHD患者斑块发生率高、稳定性差	[31]
升高	与CHD患者血管病变支数正相关	[32]
升高	与CHD患者Gensini积分正相关	[33]
预后价值
升高	预示着CHD患者的MACE发生率高	[43]
升高	以6.66作为截断值，对CHD患者住院期间不良事件预测的AUC为0.690	[38]
升高	预示着CHD患者总体死亡率、院内和远期死亡率增高	[39]

临床价值	作用	参考文献
诊断价值
升高	NLR≥2.36可作为CHD的独立危险因素	[27]
升高	NLR升高1个单位，CHD发病率增加1.6倍，诊断CHD的AUC为0.814	[26]
升高	结合CK-MB、hs-CRP、IMA诊断CHD的AUC为0.980	[28]
升高	结合中医辨证和Fib诊断CHD的AUC为0.776	[29]
病情严重程度评估价值
升高	预示着CHD患者斑块发生率高、稳定性差	[31]
升高	与CHD患者血管病变支数正相关	[32]
升高	与CHD患者Gensini积分正相关	[33]
预后价值
升高	预示着CHD患者的MACE发生率高	[43]
升高	以6.66作为截断值，对CHD患者住院期间不良事件预测的AUC为0.690	[38]
升高	预示着CHD患者总体死亡率、院内和远期死亡率增高	[39]

中性粒细胞/淋巴细胞比值在冠心病诊疗中的研究进展

Research progress on neutrophil-to-lymphocyte ratio in the diagnosis and treatment of coronary heart disease

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 49

相关文章 15

编辑推荐

Metrics

[1]	楚野, 熊春翔, 黄宇, 曾佳兴, 易波德, 黄能干, 杨屹峰, 杨枫. 基于CAR、NLR的列线图模型在预测老年髋部骨折患者术后1年内死亡中的价值[J]. 检验医学, 2025, 40(9): 834-840.
[2]	孙洋, 李守霞, 蔡会欣. 血清sd-LDL-C和AIP与冠心病严重程度的相关性[J]. 检验医学, 2025, 40(8): 757-762.
[3]	赵君, 王鹏. 基于血常规指标和NLR、PLR、MLR诊断儿童腺病毒感染[J]. 检验医学, 2025, 40(8): 817-820.
[4]	舒铭. 血清VCAM-1、Gal-3、Hcy在冠心病患者病情评估中的价值[J]. 检验医学, 2025, 40(3): 247-252.
[5]	邹珍洋, 于瑾舒, 何仁栋, 谢宁, 郭斌. GDF-15、NT-proBNP和NLR在慢性心力衰竭诊断、病情严重程度和预后评估中的价值[J]. 检验医学, 2025, 40(10): 946-953.
[6]	王梦茹, 周麟, 邢茜茜, 崔倩倩. 老年髋部骨折患者术前NLR、UA和PGE2联合检测对术后谵妄的预测价值[J]. 检验医学, 2025, 40(10): 987-991.
[7]	郭凤霞, 胡冰, 沙燕华. 冠心病患者甲基转移酶样蛋白14水平检测的价值[J]. 检验医学, 2025, 40(1): 54-58.
[8]	张爱民, 殷悦, 秦莉, 张娜, 王春燕, 贾玫, 裴林. 血清sd-LDL-C与2型糖尿病患者冠状动脉病变严重程度和心血管事件发生风险的相关性[J]. 检验医学, 2025, 40(1): 66-72.
[9]	王豪, 夏雯莹, 童巍, 邬文佳. 抑郁症患者血清脂蛋白相关磷脂酶A2水平变化及其临床意义[J]. 检验医学, 2024, 39(9): 871-874.
[10]	袁勇程, 刘尚军. CAR、NLR在阻塞性睡眠呼吸暂停低通气综合征合并高血压诊断中的价值[J]. 检验医学, 2024, 39(7): 640-644.
[11]	陈海英, 葛雅芳, 潘顺, 杨海鸥. 炎症衍生指标和胱抑素C对子痫前期的临床意义[J]. 检验医学, 2024, 39(6): 557-561.
[12]	代尧, 黎佳慧, 徐秀红. 基于肺炎支原体DNA和外周血炎症指标构建儿童肺炎支原体肺炎预后评估模型[J]. 检验医学, 2024, 39(6): 568-572.
[13]	王田, 白毅, 赵静, 解娟, 詹颉. 全身炎症指数和预后营养指数对重度胰腺炎的早期诊断价值[J]. 检验医学, 2024, 39(6): 598-601.
[14]	周瑞玲, 张新宇, 任晓玲, 张雯, 樊长征, 张琼. AECOPD患者UA/Cr比值、NLR与低氧血症的关系[J]. 检验医学, 2024, 39(5): 474-479.
[15]	李可静, 王琳, 杨宁. 老年患者NLR、TGF-β1、Cav-1水平与颅内大动脉急性闭塞机械取栓术后出血风险的关系[J]. 检验医学, 2024, 39(5): 480-484.